California Medical Products, Inc. v. Emergency Medical Products, Inc.

796 F. Supp. 640, 24 U.S.P.Q. 2d (BNA) 1205, 1992 WL 152243, 1992 U.S. Dist. LEXIS 9732
CourtDistrict Court, D. Rhode Island
DecidedJune 24, 1992
DocketCiv. A. 91-0542L
StatusPublished
Cited by1 cases

This text of 796 F. Supp. 640 (California Medical Products, Inc. v. Emergency Medical Products, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Rhode Island primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
California Medical Products, Inc. v. Emergency Medical Products, Inc., 796 F. Supp. 640, 24 U.S.P.Q. 2d (BNA) 1205, 1992 WL 152243, 1992 U.S. Dist. LEXIS 9732 (D.R.I. 1992).

Opinion

*642 MEMORANDUM AND ORDER

LAGUEUX, District Judge.

This matter is presently before the Court on plaintiffs motion for preliminary injunction pursuant to 35 U.S.C. § 283 (1988). Plaintiff California Medical Products, Inc. (“CalMed”) holds the patent for a cervical extrication collar marketed as “STIFNECK ™.” CalMed seeks to preliminarily enjoin defendant Emergency Medical Products, Inc. (“EMPI”) from manufacturing and selling its extrication collar, known as the “Ultimate Collar,” on the ground that EMPI’s collar infringes CalMed’s U.S. Patent No. RE32,219 (the '219 patent). EMPI denies any infringement and moves for summary judgment pursuant to Fed. R.Civ.P. 56(b).

I. BACKGROUND

CalMed manufactures and sells cervical extrication collars used by paramedics and emergency medical technicians to immobilize the head and neck of emergency victims during transportation, preliminary examination, and treatment. The collars consist of two pieces cut from flat sheet plastic: a neck band and a chin rest. The asymmetrical neck band encircles the patient’s neck and closes on the side with velcro. The chin rest is permanently attached to the neck band at two locations: one end of the chin rest is fastened to the side of the neck band, and the center of the chin rest is fastened to a tab extending from the upper edge of the neck band. The other end of the chin rest remains unattached until ready for use, enabling the collar to be stored flat. Prior to application, the free end of the chin rest is snapped in place, and the collar forms a cylindrical shape that can be readily slipped around the neck of a prone patient and secured. The collars are made of radiolucent plastic that allows X-rays to be taken while the collar is worn. Geoffrey Garth, CalMed’s president and the inventor of STIFNECK™, received the patent for his unique collar design in 1983. CalMed now occupies about two-thirds of the extrication collar market.

When EMPI sought to enter the extrication collar field, its president, William Burns, examined all those collars already on the market to find the best design. After surveying the field, EMPI began producing cervical extrication collars almost exactly like CalMed’s. STIFNECK™. When CalMed became aware of this, CalMed requested that EMPI cease and desist its infringing activity. EMPI denied any infringement. Consequently, CalMed filed this action.

In October 1991 EMPI redesigned its Ultimate Collar by widening the tab that extends from the upper edge of the neck band and deepening the gaps on either side of the tab. EMPI claims that this new design does not infringe CalMed’s patent because these modifications distinguish the Ultimate Collar from the ’219 patent claims, especially the claims stating that the chin rest is “supported along its entire length” by the upper edge of the neck band. Recently, EMPI has produced the same design in foam, marketed as the “EXL Disposable Collar.” These two models (Pl.’s Ex. 5, the hard collar; Pl.’s Ex. 10, the foam collar) are the subjects of plaintiff’s motion for preliminary injunction and defendant’s motion for summary judgment. 1 After conducting a full evidentiary hearing, the Court took the matter under advisement. The motions are now in order for decision.

II. CALMED’S MOTION FOR PRELIMINARY INJUNCTION

In deciding a motion for preliminary injunction, this Court must consider the following factors:

1) CalMed’s reasonable likelihood of success on the merits;
2) the potential for irreparable injury to CalMed if relief is denied;
*643 3) the balance of hardships tipping in CalMed’s favor; and
4) the impact of the injunction on the public interest.

Hybritech Inc. v. Abbott Lab., 849 F.2d 1446, 1451 (Fed.Cir.1988); see also Narragansett Indian Tribe v. Guilbert, 934 F.2d 4, 5 (1st Cir.1991).

A. Reasonable Likelihood of Success on the Merits

CalMed must first establish its reasonable likelihood of success on the issue of patent validity. Hybritech, 849 F.2d at 1451. A patent is born valid, and its validity endures until a challenger has “so carried his burden as to have persuaded the decisionmaker that the patent can no longer be accepted as valid.” Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1534 (Fed.Cir.1983); see 35 U.S.C. § 282 (1988). In order to meet its burden of persuasion, EMPI would have to demonstrate at trial, by clear and convincing evidence, that the ’219 patent is invalid. Loctite Corp. v. Ultraseal Ltd., 781 F.2d 861, 872 (Fed.Cir.1985). On this motion for preliminary injunction CalMed must show that EMPI would fail to prove such invalidity. H.H. Robertson, Co. v. United Steel Deck, Inc., 820 F.2d 384, 387-88 (Fed.Cir.1987).

At present, EMPI has asserted no basis for invalidity. In response to CalMed’s motion for preliminary injunction, EMPI fails to discuss the issue of invalidity, focusing only on the issue of infringement. Furthermore, EMPI assumes the validity of the ’219 patent for the purposes of its summary judgment motion.

On three prior occasions, CalMed sought to enjoin infringement of the ’219 patent. Each of these actions resulted in a consent judgment in which the infringing party acknowledged the validity of the ’219 patent and agreed to a permanent injunction. While these consent judgments do not constitute prior adjudications of the ’219 patent’s validity, they nevertheless indicate the patent’s validity because of the infringing parties’ acquiescence. Id. at 388. For these reasons the Court finds it reasonably likely that EMPI would fail to prove the ’219 patent invalid at trial.

Next, the Court must consider CalMed’s reasonable likelihood of success on the issue of infringement. Hybritech, 849 F.2d at 1451. The grant of a preliminary injunction does not require the moving party to prove beyond all question that there has been infringement, nor to prove that no evidence exists to support the accused infringer’s arguments. H.H. Robertson, 820 F.2d at 390. Instead, CalMed must show a reasonable likelihood that it will meet its burden at trial by proving either literal infringement or infringement by equivalents. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
796 F. Supp. 640, 24 U.S.P.Q. 2d (BNA) 1205, 1992 WL 152243, 1992 U.S. Dist. LEXIS 9732, Counsel Stack Legal Research, https://law.counselstack.com/opinion/california-medical-products-inc-v-emergency-medical-products-inc-rid-1992.